Harbour BioMed inks agreement for ‘next generation biologic discovery’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ anusorn nakdee)
(Image: Getty/ anusorn nakdee)

Related tags: Biologics, Drug discovery, Immunology, Immunotherapy, Drug development, Drug development process

Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.

Harbour BioMed’s platform for heavy chain only antibodies (HCAbs) generates fully human heavy chain antibodies to be used to accelerate the discovery and development of biologic therapeutics. 

Jinhson Wang, CEO of Harbour BioMed said in a statement, “Drug discovery in the burgeoning fields of immuno-oncology and immunotherapy is relying increasingly on advanced biological approaches to selectively attack one or more immune targets and modulate the immune system to treat cancer and other diseases.”

Harbour has used its HCAb platform in other discovery and development programs to create alternatives for domain antibodies, bi-specific and multi-specific antibodies, and chimeric antigen receptor (CAR) T-cell therapies.

“The HCAb platform is emerging as a powerful technology to enable next generation biologic discovery for our internal portfolio and a select group of licensing partners,”​ Wang further explained.

While Harbour has not released the name of its licensing partner, it did state that the company was a global pharmaceutical organization specializing in immunology and immune-oncology.

Through this agreement, Harbour will receive an undisclosed upfront payment and will be eligible to receive further development and sales related milestone payments and royalties.

In June of 2018 WuXi Biologics and Harbour entered an agreement​ with WuXi Biologics to develop and manufacture ‘heavy chain only’ antibodies. Per that deal, WuXi provided services to supply Harbour’s products for clinical trials.

Related news

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars